Search - tctmd.com

Displaying 41 - 60 of 117

Sort: Relevancy | Date

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

News Conference News ACC 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Yael L. Maxwell

May 17, 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

May 16, 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

News Conference News ACC 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Yael L. Maxwell

May 15, 2021

Poorer Neighborhoods Pose Risks for Black Patients After Acute MI

News Conference News ACC 2021

Poorer Neighborhoods Pose Risks for Black Patients After Acute MI

May 05, 2021

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

News Conference News ACC 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

March 29, 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

News Conference News ACC 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

Yael L. Maxwell

March 28, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

March 28, 2020

News Conference News ACC 2020

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Michael O'Riordan

March 28, 2020

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

News Conference News ACC 2019

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Yael L. Maxwell

March 25, 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.